The vesicular monoamine transporter 2: An underexplored pharmacological target

Neurochemistry International

Volumn 73, Issue 1, 2014, Pages 89-97

  Bernstein, Alison I ^a   Stout, Kristen A ^a   Miller, Gary W ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

SLC18A2; Transport; Vesicle; VMAT2

Indexed keywords

AMPHETAMINE; APOMORPHINE; LEVODOPA; METHYLPHENIDATE; NEUROTRANSMITTER TRANSPORTER; PRAMIPEXOLE; RESERPINE; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2; SLC18A2 PROTEIN, HUMAN;

ACTIVE TRANSPORT; ADRENERGIC SYSTEM; ARTICLE; CELL DAMAGE; CELL DEATH; CELL MEMBRANE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; HIGH THROUGHPUT SCREENING; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; MONOAMINERGIC SYSTEM; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR OCCUPANCY; SYMPATHETIC TONE; SYNAPSE VESICLE; UPREGULATION; ANIMAL; DRUG EFFECTS; MENTAL DISORDERS; METABOLISM; NERVOUS SYSTEM DISEASES;

ANIMALS; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84902548870     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2013.12.003     Document Type: Review

References (136)

1. S.P. Alter, G.M. Lenzi, A.I. Bernstein, and G.W. Miller Vesicular integrity in Parkinson's disease Curr. Neurol. Neurosci. Rep. 13 2013 362
2. M. Asanuma, I. Miyazaki, and N. Ogawa Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease Neurotox. Res. 5 2003 165 176
3. A. Ascherio et al. Pesticide exposure and risk for Parkinson's disease Ann. Neurol. 60 2006 197 203
4. E.E. Bellocchio, R.J. Reimer, R.T. Fremeau, and R.H. Edwards Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter Science 289 2000 957 960
5. J.C. Bemis, and R.F. Seegal PCB-induced inhibition of the vesicular monoamine transporter predicts reductions in synaptosomal dopamine content Toxicol. Sci. 80 2004 288 295
6. D. Benshachar, R. Zuk, and Y. Glinka Dopamine neurotoxicity - inhibition of mitochondrial respiration J. Neurochem. 64 1995 718 723
7. A.I. Bernstein, K.A. Stout, and G.W. Miller A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport J. Neurosci. Methods 209 2012 357 366
8. J.M. Bradner et al. Exposure to the polybrominated diphenyl ether mixture DE-71 damages the nigrostriatal dopamine system: role of dopamine handling in neurotoxicity Exp. Neurol. 241 2013 138 147
9. K.J. Broadley, and C.D. Nicholson The use of an irreversible beta-adrenoreceptor antagonist to examine reserpine- and hypothermia-induced supersensitivity of guinea-pig atria J. Auton. Pharmacol. 1 1980 27 35
10. B.B. Brodie, P.A. Shore, and S.L. Silver Potentiating action of chlorpromazine and reserpine Nature 175 1955 1133 1134
11. I. Brunk et al. The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake J. Biol. Chem. 281 2006 33373 33385
12. I. Brunk et al. Deletion of Go2alpha abolishes cocaine-induced behavioral sensitization by disturbing the striatal dopamine system FASEB J. 22 2008 3736 3746
13. W.J. Burke et al. Neurotoxicity of MAO Metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases Neurotoxicology 25 2004 101 115
14. W.M. Caudle, J.R. Richardson, M. Wang, and G.W. Miller Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum Neurotoxicology 26 2005 721 728
15. W.M. Caudle et al. Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity Toxicol. Sci. 92 2006 490 499
16. W.M. Caudle et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration J. Neurosci. 27 2007 8138 8148
17. W.M. Caudle, T.S. Guillot, C.R. Lazo, and G.W. Miller Industrial toxicants and Parkinson's disease Neurotoxicology 33 2012 178 188
18. S. Chandra et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions Proc. Natl. Acad. Sci. USA 101 2004 14966 14971
19. H.Y. Chang et al. Overexpression of the Drosophila vesicular monoamine transporter increases motor activity and courtship but decreases the behavioral response to cocaine Mol. Psychiatry 11 1 2006 99 113
20. F.A. Chaudhry, R.H. Edwards, and F. Fonnum Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances Annu. Rev. Pharmacol. Toxicol. 48 2008 277 301
21. L. Chen et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice J. Neurosci. 28 2008 425 433
22. J.J. Chen, W.G. Ondo, K. Dashtipour, and D.M. Swope Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature Clin. Ther. 34 2012 1487 1504
23. B. Chernow, G.P. Zaloga, C.R. Lake, M.D. Coleman, and M.G. Ziegler Effect of antihypertensive therapy on sympathetic nervous system activity in patients with essential hypertension Fed. Proc. 43 1984 72 77
24. P.-W. Chu et al. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release J. Neurochem. 115 2010 325 332
25. R.E. Colebrooke et al. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease Eur. J. Neurosci. 24 2006 2622 2630
26. W.S. Davidson, A. Jonas, D.F. Clayton, J.M. George, and A. Jones Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes J. Biol. Chem. 273 1998 9443 9449
27. G. Eisenhofer, I.J. Kopin, and D.S. Goldstein Leaky catecholamine stores: undue waste or a stress response coping mechanism? Ann. N.Y. Acad. Sci. 1018 2004 1 7
28. A. Elbaz et al. Professional exposure to pesticides and Parkinson disease Ann. Neurol. 66 2009 494 504
29. J.D. Erickson, L.E. Eiden, and B.J. Hoffman Expression cloning of a reserpine-sensitive vesicular monoamine transporter Proc. Natl. Acad. Sci. USA 89 1992 10993 10997
30. J.D. Erickson et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter Proc. Natl. Acad. Sci. USA 93 1996 5166 5171
31. A. Fasano, and A.R. Bentivoglio Tetrabenazine Expert Opin. Pharmacother. 10 2009 2883 2896
32. A.E. Fleckenstein, T.J. Volz, E.L. Riddle, J.W. Gibb, and G.R. Hanson New insights into the mechanism of action of amphetamines Annu. Rev. Pharmacol. Toxicol. 47 2007 681 698
33. F. Fonnum, E. Mariussen, and T. Reistad Molecular mechanisms involved in the toxic effects of polychlorinated biphenyls (PCBs) and brominated flame retardants (BFRs) J. Toxicol. Environ. Health 69 2006 21 35
34. F. Fonnum, E. Mariussen, and T. Reistad Mechanisms involved in the neurotoxic effects of environmental toxicants such as polychlorinated biphenyls and brominated flame retardants J. Neurochem. 111 2009 1327 1347
35. E.D. Freis Mental depression in hypertensive patients treated for long periods with large doses of reserpine N. Engl. J. Med. 251 1954 1006 1008
36. A. Furlenmeier, R. Lucas, H.B. Macphillamy, J.M. Muller, and E. Schlittler On the constitution of reserpine Experientia 9 1953 331 333
37. R.R. Gainetdinov et al. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice J. Neurochem. 70 1998 1973 1978
38. N.M. Gatto, M. Cockburn, J. Bronstein, A.D. Manthripragada, and B. Ritz Well-water consumption and Parkinson's disease in rural California Environ. Health Perspect. 117 2009 1912 1918
39. M.S. Goldberg et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1 Neuron 45 2005 489 496
40. J.C. Goldstein, N.J. Waterhouse, P. Juin, G.I. Evan, and D.R. Green The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant Nat. Cell Biol. 2 2000 156 162
41. D.S. Goldstein et al. Catechols in post-mortem brain of patients with Parkinson disease Eur. J. Neurol. 18 2011 703 710
42. D.G. Graham, S.M. Tiffany, W.R. Bell, and W.F. Gutknecht Autoxidation versus covalent binding of quinones as mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward c1300-neuroblastoma cells invitro Mol. Pharmacol. 14 1978 644 653
43. Group HS Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial Neurology 66 2006 366 372
44. D.R. Guay Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders Am. J. Geriatr. Pharmacother. 8 2010 331 373
45. N.G. Gubernator et al. Fluorescent false neurotransmitters visualize dopamine release from individual presynaptic terminals Science 324 2009 1441 1444
46. T.S. Guillot et al. PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity Neuropeptides 42 2008 423 434
47. T.S. Guillot et al. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis J. Neurochem. 106 2008 2205 2217
48. G.R. Hanson, V. Sandoval, E. Riddle, and A.E. Fleckenstein Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications Ann. N.Y. Acad. Sci. 1025 2004 146 150
49. T.G. Hastings, D.A. Lewis, and M.J. Zigmond Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections Proc. Natl. Acad. Sci. USA 93 1996 1956 1961
50. J.M. Hatcher, K.C. Delea, J.R. Richardson, K.D. Pennell, and G.W. Miller Disruption of dopamine transport by DDT and its metabolites Neurotoxicology 29 2008 682 690
51. M. Höltje et al. The neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go2 J. Neurosci. 20 2000 2131 2141
52. M. Höltje et al. The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake J. Biol. Chem. 278 2003 15850 15858
53. D.B. Horton, J.R. Nickell, G. Zheng, P.A. Crooks, and L.P. Dwoskin GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine J. Neurochem. 127 2013 177 186
54. L.L. Howell, and H.L. Kimmel Monoamine transporters and psychostimulant addiction Biochem. Pharmacol. 75 2008 196 217
55. G. Hu et al. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2) ACS Chem. Biol. 8 2013 1947 1954
56. P.H. Jensen Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation J. Biol. Chem. 273 1998 26292 26294
57. E. Jo, J. McLaurin, C.M. Yip, P. St George-Hyslop, and P.E. Fraser Alpha-Synuclein membrane interactions and lipid specificity J. Biol. Chem. 275 2000 34328 34334
58. S. Kariya, N. Takahashi, M. Hirano, and S. Ueno Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice J. Mol. Neurosci. 27 2005 277 279
59. R.J. Karpowicz, M. Dunn, D. Sulzer, and D. Sames APP+, a fluorescent analogue of the neurotoxin MPP+, is a marker of catecholamine neurons in brain tissue, but not a fluorescent false neurotransmitter ACS Chem. Neurosci. 4 2013 858 869
60. T. Kitada et al. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice Proc. Natl. Acad. Sci. USA 104 2007 11441 11446
61. T. Kitada et al. Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice J. Neurochem. 110 2009 613 621
62. T. Kitada, Y. Tong, C.A. Gautier, and J. Shen Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice J. Neurochem. 111 2009 696 702
63. M. Kitazawa, V. Anantharam, and a.G. Kanthasamy Dieldrin induces apoptosis by promoting caspase-3-dependent proteolytic cleavage of protein kinase Cδ in dopaminergic cells: relevance to oxidative stress and dopaminergic degeneration Neuroscience 119 2003 945 964
64. J. Knoth, M. Zallakian, and D. Njus Stoichiometry of H+-linked dopamine transport in chromaffin granule ghosts Biochemistry 20 1981 6625 6629
65. H.O. Lawal et al. Drosophila modifier screens to identify novel neuropsychiatric drugs including aminergic agents for the possible treatment of Parkinson's disease and depression Mol. Psychiatry 10 2012 1 8
66. D.W. Lee, and Opanashuk. La Polychlorinated biphenyl mixture aroclor 1254-induced oxidative stress plays a role in dopaminergic cell injury Neurotoxicology 25 2004 925 939
67. M. Lee, N.G. Gubernator, D. Sulzer, and D. Sames Development of pH responsive fluorescent false neurotransmistters J. Am. Chem. Soc. 132 2010 8828 8830
68. N. Lev et al. DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging J Gerontol. A Biol. Sci. Med. Sci. 68 2013 215 225
69. Y. Liu, and R.H. Edwards The role of vesicular transport proteins in synaptic transmission and neural degeneration Annu. Rev. Neurosci. 20 1997 125 156
70. Y. Liu et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter Cell 70 1992 539 551
71. Y. Liu, A. Roghani, and R.H. Edwards Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium Proc. Natl. Acad. Sci. USA 89 1992 9074 9078
72. M. Mahata, S.K. Mahata, R.J. Parmer, and D.T. O'Connor Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion Hypertension 28 1996 414 420
73. E. Mariussen, and F. Fonnum The effect of polychlorinated biphenyls on the high affinity uptake of the neurotransmitters, dopamine, serotonin, glutamate and GABA, into rat brain synaptosomes Toxicology 159 2001 11 21
74. E. Mariussen, and F. Fonnum The effect of brominated flame retardants on neurotransmitter uptake into rat brain synaptosomes and vesicles Neurochem. Int. 43 2003 533 542
75. G.W. Miller, R.R. Gainetdinov, A.I. Levey, and M.G. Caron Dopamine transporters and neuronal injury Trends Pharmacol. Sci. 20 1999 424 429
76. D.K. Miller et al. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters J. Pharmacol. Exp. Ther. 310 2004 1035 1045
77. V.A. Morais, P. Verstreken, A. Roethig, J. Smet, A. Snellinx, M. Vanbrabant, D. Haddad, C. Frezza, W. Mandemakers, D. Vogt-Weisenhorn, R. Van Coster, W. Wurst, L. Scorrano, and B. De Strooper Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function EMBO mol. med. 1 2009 99 111
78. E.V. Mosharov et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons Neuron 62 2009 218 229
79. C.W. Olanow, Obeso. Ja, and F. Stocchi Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease Nat. Clin. Pract. Neurol. 2 2006 382 392
80. W.G. Ondo, R. Tintner, M. Thomas, and J. Jankovic Tetrabenazine treatment for Huntington's disease-associated chorea Clin. Neuropharmacol. 25 2002 300 302
81. D. Paleacu et al. Tetrabenazine treatment in movement disorders Clin. Neuropharmacol. 27 2004 230 233
82. L.L.A. Parra et al. The orphan transporter Rxt1/NTT4 (SLC6A17) functions as a synaptic vesicle amino acid transporter selective for proline, glycine, leucine and alanine Mol. Pharmacol. 74 2008 1521 1532
83. S. Parsons Transport mechanisms in acetylcholine and monoamine storage FASEB J. 14 2000 2423 2434
84. N.R.N.R. Penthala et al. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2) Bioorg. Med. Chem. Lett. 23 2013 3342 3345
85. R.J. Perrin, W.S. Woods, D.F. Clayton, and J.M. George Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis J. Biol. Chem. 275 2000 34393 34398
86. B. Picconi et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia Nat. Neurosci. 6 2003 501 506
87. A. Pletscher, P. Shore, and B. Brodie Serotonin release as a possible mechanism of reserpine action Science 122 1955 364 365
88. A. Priyadarshi, S.A. Khuder, E.A. Schaub, and S. Shrivastava A meta-analysis of Parkinson's disease and exposure to pesticides Neurotoxicology 21 2000 435 440
89. A. Priyadarshi, S.A. Khuder, E.A. Schaub, and S.S. Priyadarshi Environmental risk factors and Parkinson's disease: a metaanalysis Environ. Res. 86 2001 122 127
90. Rasband, W. ImageJ. US National Institutes of Health, Bethesda, Maryland, USA.
91. L.A. Raymond et al. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function Neuroscience 198 2011 252 273
92. J.N. Rees, V.R. Florang, L.L. Eckert, and J.A. Doorn Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol Chem. Res. Toxicol. 22 2009 1256 1263
93. H. Rhinn et al. Alternative α-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology Nat. Commun. 3 2012 1084
94. J.R. Richardson, and G.W. Miller Acute exposure to aroclor 1016 or 1260 differentially affects dopamine transporter and vesicular monoamine transporter 2 levels Toxicol. Lett. 148 2004 29 40
95. J.R. Richardson et al. Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease FASEB J. 20 2006 1695 1697
96. A. Richman, and J.S. Tyhurst An extrapyramidal syndrome with reserpine Can. Med. Assoc. J. 72 1955 457 458
97. B. Ritz Parkinson's disease mortality and pesticide exposure in California 1984-1994 Int. J. Epidemiol. 29 2000 323 329
98. Rodriguez, PC., et al. 2013. Fluorescent dopamine tracer resolves individual dopaminergic synapses and their activity in the brain. Proc. Natl. Acad. Sci. USA
99. V.A. Russell Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat Behav. Brain Res. 130 2002 191 196
100. J. Sanchez-Ramos, A. Facca, A. Basit, and S. Song Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures Exp. Neurol. 150 1998 263 271
101. V. Sandoval, E.L. Riddle, G.R. Hanson, and A.E. Fleckenstein Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors J Neurosci. 22 2002 8705 8710
102. S. Schuldiner Vesicular neurotransmitter transporters: from bacteria to humans. AccessMyLibrary - Promoting library advocacy Physiol. Rev. 75 1995 369 392
103. K. Schwartz, G. Yadid, A. Weizman, and M. Rehavi Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression Brain Res. 965 2003 174 179
104. L.J. Scott Tetrabenazine: for chorea associated with Huntington's disease CNS Drugs 25 2011 1073 1085
105. R.F. Seegal The neurotoxicological consequences of developmental exposure to PCBs Toxicol. Sci. 57 2000 1 3
106. R. Seegal, K. Brosch, and B. Bush Polychlorinated biphenyls produce regional alterations of dopamine metabolism in rat brain Toxicol. Lett. 30 1986 197 202
107. R. Seegal, B. Bush, and W. Shain Lightly Chlorinated ortho-substituted PCB congeners decrease dopamine in nonhuman primate brain and in tissue culture Toxicol. Appl. Pharmacol. 106 1990 136 144
108. K.M. Semchuk, E.J. Love, and R.G. Lee Parkinson's disease and exposure to rural environmental factors: a population based case-control study Can. J. Neurol. Sci. 18 1991 279 286
109. K.M. Semchuk, E.J. Love, and R.G. Lee Parkinson's disease and exposure to agricultural work and pesticide chemicals Neurology 42 1992 1328 1335
110. S.L. Senior et al. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein Eur. J. Neurosci. 27 2008 947 957
111. E. Solis et al. 4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+) is a fluorescent substrate for the human serotonin transporter J. Biol. Chem. 287 2012 8852 8863
112. C.-H. Song, X. Fan, C.J. Exeter, E.J. Hess, and H.A. Jinnah Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia Neurobiol. Dis. 48 2012 66 78
113. K. Steenland et al. Polychlorinated biphenyls and neurodegenerative disease mortality in an occupational cohort Epidemiology 17 2006 8 13
114. T.C. Sudhof The synaptic vesicle cycle Annu. Rev. Neurosci. 27 2004 509 547
115. D. Sulzer, and L. Zecca Intraneuronal dopamine-quinone synthesis: a review Neurotox. Res. 1 1999 181 195
116. D. Sulzer, M.S. Sonders, N.W. Poulsen, and A. Galli Mechanisms of neurotransmitter release by amphetamines: a review Prog. Neurobiol. 75 2005 406 433
117. N. Takahashi et al. VMAT2 knockout mice. Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity Proc. Natl. Acad. Sci. USA 94 1997 9938 9943
118. C.M. Tanner, and D.A. Aston Epidemiology of Parkinson's disease and akinetic syndromes Curr. Opin. Neurol. 13 2000 427 430
119. C.M. Tanner, and J.W. Langston Do environmental toxins cause Parkinson's disease? A critical review Neurology 1990 40 suppl 1990 17 30 (discussion 30-31)
120. C.M. Tanner et al. Rotenone, paraquat, and Parkinson's disease Environ. Health Perspect. 119 2011 866 872
121. S.F. Taylor, R.A. Koeppe, R. Tandon, J.K. Zubieta, and K.A. Frey In vivo measurement of the vesicular monoamine transporter in schizophrenia Neuropsychopharmacology 23 2000 667 675
122. T.N. Taylor et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity J. Neurosci. 29 2009 8103 8113
123. D.M. Thomas, D.M. Francescutti-Verbeem, and D.M. Kuhn The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity J. Neurochem. 105 2008 605 616
124. J.G. Truong, K.S. Rau, G.R. Hanson, and A.E. Fleckenstein Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration Eur. J. Pharmacol. 474 2003 223 226
125. J.G. Truong, G.R. Hanson, and A.E. Fleckenstein Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration Eur. J. Pharmacol. 492 2004 143 147
126. A. Ulusoy, T. Björklund, K. Buck, and D. Kirik Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons Neurobiol. Dis. 47 2012 367 377
127. Y. Usami et al. DJ-1 associates with synaptic membranes Neurobiol. Dis. 43 2011 651 662
128. M.J. Volles et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease Biochemistry 40 2001 7812 7819
129. T.J. Volz, S.J. Farnsworth, G.R. Hanson, and A.E. Fleckenstein Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue J. Neurosci. Methods 180 2009 317 320
130. Y.M. Wang et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine Neuron 19 1997 1285 1296
131. E. Weihe, M.K. Schäfer, J.D. Erickson, and L.E. Eiden Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat J. Mol. Neurosci. 5 1994 149 164
132. M.C. Wey et al. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease PLoS ONE 7 2012 e31522
133. Z. Yao et al. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors Eur. J. Med. Chem. 46 2011 1841 1848
134. M. Zahid et al. Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease IUBMB Life 63 2011 1087 1093
135. G. Zheng, L.P. Dwoskin, and Crooks. Pa Vesicular monoamine transporter 2: role as a novel target for drug development AAPS J. 8 2006 E682 E692
136. P. Zheng, B.P. Lieberman, S. Rye, K. Plöessl, and H.F. Kung Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands Bioorg. Med. Chem. Lett. 21 2011 3435 3438